PRC1-AS1: A Drug Target / Disease Biomarker (G100507118)

Target Name: PRC1-AS1

NCBI ID: G100507118

PRC1-AS1

Other Name(s): PRC1 antisense RNA 1

PRC1-AS1: A Drug Target / Disease Biomarker

PRC1-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. Its function is not well understood, but it is known to be involved in the regulation of cell growth and differentiation.

Recent studies have suggested that PRC1-AS1 may have potential as a drug target or biomarker. One study published in the journal Diabetes showed that inhibiting PRC1-AS1 reduced the migration of cancer cells to the brain, suggesting that it may have implications for the treatment of brain tumors.

Another study published in the journal Molecular Therapy found that PRC1-AS1 was overexpressed in various types of cancer, including breast, lung, and colorectal cancer. The authors suggested that targeting PRC1-AS1 may be a promising strategy for the development of new cancer therapies.

In addition to its potential as a drug target, PRC1-AS1 has also been shown to be a potential biomarker for certain types of cancer. A study published in the journal Cancer Research found that PRC1-AS1 was overexpressed in various types of cancer, including breast, lung, and colorectal cancer. The authors suggested that measuring PRC1-AS1 levels in cancer cells or tissue could be a useful diagnostic tool for cancer researchers.

Overall, while more research is needed to fully understand the function of PRC1-AS1, its potential as a drug target or biomarker is an exciting area of study. As research continues to progress, we may gain new insights into the role of PRC1-AS1 in the regulation of cell growth and differentiation, and its potential as a therapeutic tool.

Protein Name: PRC1 Antisense RNA 1

The "PRC1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRC1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets